DNA Sequencing Global Strategic Research Report 2024: Growing Adoption of Sequencing Services in Clinical Workflows Propels Market Growth - Global Forecast to 2030
August 29, 2024 10:50 ET
|
Research and Markets
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The "DNA Sequencing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for DNA Sequencing is...
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
August 08, 2024 16:15 ET
|
Kronos Bio, Inc.
— First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558...
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
July 23, 2024 16:15 ET
|
Kronos Bio, Inc.
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and...
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:15 ET
|
Kronos Bio, Inc.
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742 continues to show dose linear pharmacokinetics up to 80mg...
XARELTO Market Size, Forecast, and Market Insight to 2032, with Focus on the United States and Japan
April 04, 2024 11:13 ET
|
Research and Markets
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "XARELTO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
March 05, 2024 16:44 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Global Factor IX Drug Pipeline Landscape Report 2024: Therapeutic Assessment by Stage, Route of Administration, and Molecule Type
February 29, 2024 10:52 ET
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Factor IX - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
Global Menin Inhibitor Drugs Clinical Trials & Insight Report 2023 Featuring Biomea Fusion, BioNova, Daiichi Sankyo, Easton, Eilean Therapeutics, HitGen, Janssen, and Sumitomo
December 15, 2023 04:48 ET
|
Research and Markets
Dublin, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering. ...
Menin Inhibitors Drugs Clinical Insight
September 29, 2023 02:16 ET
|
KuicK Research
Delhi, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 Report Highlights: Research MethodologyMenin Inhibitors Drugs In...
Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana Therapeutics, Homology Medicines
July 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Phenylketonuria Market to Exhibit Significant Growth, Assesses DelveInsight | Key Companies - BioMarin, Synlogic, PTC Therapeutics, Jnana...